A-3 Price List - Leukemia Lymphoma Agents-BTKI.xlsx

XLSX spreadsheet 45 KB Posted

Attached to
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Solicitation number
HT9402-24-Q-9301
Issued by

About this file

This document is a Request for Quotation (RFQ) related to the Department of Defense (DoD) Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program. The DoD is soliciting quotes from industry for pharmaceutical agents within certain drug classes, including Leukemia and Lymphoma Agents: Bruton Tyrosine Kinase Inhibitors, to be considered for placement on the DoD Uniform Formulary (UF) at the August 2024 Pharmacy and Therapeutics (P&T) Committee meeting.

The RFQ provides details on the UF BPA and UF ADP agreements that may be awarded based on the P&T Committee's formulary decisions. Key details include the requirement for manufacturers to submit quotes by June 13, 2024, information on formulary placement scenarios and pricing bands, and requirements for additional discounts and refunds for TRICARE retail prescriptions. The RFQ also includes instructions for the pre-quote teleconference on April 24, 2024 and the submission of responses to clinical questions.

View the file

Other files

File Type Posted
RFQ HT9402-24-Q-9301 CR.pdf PDF
Amendment 0001 CR.pdf PDF
August 24 DoD P and T Reporting Data.xlsx XLSX spreadsheet
A-3 Price List - Antipsychotic Agents - Parkinsons.xlsx XLSX spreadsheet
RFQ HT9402-23-Q-9301 CR.pdf PDF
NDC Price List FAQ Class Review.pdf PDF
A-3 Price List - Antilipidemics-1 - Statins.xlsx XLSX spreadsheet
A-3 Price List - Antilipidemics-1 - Non-Statins and Combos.xlsx XLSX spreadsheet

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

BPA

UF BPA NDC Price List for the August 2024 DoD P&T Meeting
DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
Formulary Notes
Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoD P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoD P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Grandfathering. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.

Based on available government prices and historical information, the band of prices for net ingredient cost may trigger formulary considerations.

Scenario 1:

Uniform Formulary and/or Tier 2 before step therapy for the CLL/SLL indication with a specialist bypass (no PA required) for hematologists and oncologists may be considered if ingredient cost is ≤ $6,000 average per 30 days of therapy.

Uniform Formulary and/or Tier 2 after step therapy may be considered if ingredient cost is > $6,000 average per 30 days of therapy.

Scenario 2:

Uniform Formulary and/or Tier 2 may be considered if ingredient cost is ≤ $7,000 average per 30 days of therapy. Agents meeting the Uniform Formulary price band may be considered for a specialist bypass (no PA required) for hematologists and oncologists.

Non-Formulary and/or Tier 3 may be considered if ingredient cost is > $7,000 average per 30 days of therapy.

All Scenarios: Agents with RFQ not submitted or selected may be designated non-step preferred.

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.

Blanket Purchase Agreement Appendix – Class Review

#1DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1UFBS1MUniform Formulary
Before Step Thereapy1 or moreNO QUOTE
244LLBTG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
244LLBTG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1UF1MUniform Formulary1 or moreNO QUOTE
244LLBTG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#2DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1UFBS1MUniform Formulary
Before Step Thereapy1 or moreNO QUOTE
244LLBTG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
244LLBTG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1UF1MUniform Formulary1 or moreNO QUOTE
244LLBTG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#3DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1UFBS1MUniform Formulary
Before Step Thereapy1 or moreNO QUOTE
244LLBTG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
244LLBTG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1UF1MUniform Formulary1 or moreNO QUOTE
244LLBTG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#4DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1UFBS1MUniform Formulary
Before Step Thereapy1 or moreNO QUOTE
244LLBTG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
244LLBTG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1UF1MUniform Formulary1 or moreNO QUOTE
244LLBTG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#5DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
1.00
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1UFBS1MUniform Formulary
Before Step Thereapy1 or more1.00NO QUOTE
244LLBTG1UFAS1MUniform Formulary
After Step Therapy1 or more1.00NO QUOTE
244LLBTG1NFAS1MNon-Formulary
After Step Therapy1 or more1.00NO QUOTE
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1UF1MUniform Formulary1 or more1.00NO QUOTE
244LLBTG1NF1MNon-Formulary1 or more1.00NO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#6DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1UFBS1MUniform Formulary
Before Step Thereapy1 or moreNO QUOTE
244LLBTG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
244LLBTG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1UF1MUniform Formulary1 or moreNO QUOTE
244LLBTG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#7DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1UFBS1MUniform Formulary
Before Step Thereapy1 or moreNO QUOTE
244LLBTG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
244LLBTG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1UF1MUniform Formulary1 or moreNO QUOTE
244LLBTG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#8DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1UFBS1MUniform Formulary
Before Step Thereapy1 or moreNO QUOTE
244LLBTG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
244LLBTG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1UF1MUniform Formulary1 or moreNO QUOTE
244LLBTG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#9DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1UFBS1MUniform Formulary
Before Step Thereapy1 or moreNO QUOTE
244LLBTG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
244LLBTG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1UF1MUniform Formulary1 or moreNO QUOTE
244LLBTG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#10DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1UFBS1MUniform Formulary
Before Step Thereapy1 or moreNO QUOTE
244LLBTG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
244LLBTG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1UF1MUniform Formulary1 or moreNO QUOTE
244LLBTG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

ADP (non-FAMP Discount)

UF ADP Discount Table for the August 2024 DoD P&T Meeting
DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
Formulary Notes
Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoD P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoD P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Grandfathering. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.

Based on available government prices and historical information, the band of prices for net ingredient cost may trigger formulary considerations.

Scenario 1:

Uniform Formulary and/or Tier 2 before step therapy for the CLL/SLL indication with a specialist bypass (no PA required) for hematologists and oncologists may be considered if ingredient cost is ≤ $6,000 average per 30 days of therapy.

Uniform Formulary and/or Tier 2 after step therapy may be considered if ingredient cost is > $6,000 average per 30 days of therapy.

Scenario 2:

Uniform Formulary and/or Tier 2 may be considered if ingredient cost is ≤ $7,000 average per 30 days of therapy. Agents meeting the Uniform Formulary price band may be considered for a specialist bypass (no PA required) for hematologists and oncologists.

Non-Formulary and/or Tier 3 may be considered if ingredient cost is > $7,000 average per 30 days of therapy.

All Scenarios: Agents with RFQ not submitted or selected may be designated non-step preferred.

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.

Additional Discount Program Appendix – Class Review

#1DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1T2BS1MTier 2
Before Step Therapy1 or more
244LLBTG1T2AS1MTier 2
After Step Therapy1 or more
244LLBTG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1T21MTier 21 or more
244LLBTG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#2DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1T2BS1MTier 2
Before Step Therapy1 or more
244LLBTG1T2AS1MTier 2
After Step Therapy1 or more
244LLBTG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1T21MTier 21 or more
244LLBTG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#3DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1T2BS1MTier 2
Before Step Therapy1 or more
244LLBTG1T2AS1MTier 2
After Step Therapy1 or more
244LLBTG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1T21MTier 21 or more
244LLBTG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#4DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1T2BS1MTier 2
Before Step Therapy1 or more
244LLBTG1T2AS1MTier 2
After Step Therapy1 or more
244LLBTG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1T21MTier 21 or more
244LLBTG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#5DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1T2BS1MTier 2
Before Step Therapy1 or more
244LLBTG1T2AS1MTier 2
After Step Therapy1 or more
244LLBTG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1T21MTier 21 or more
244LLBTG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#6DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1T2BS1MTier 2
Before Step Therapy1 or more
244LLBTG1T2AS1MTier 2
After Step Therapy1 or more
244LLBTG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1T21MTier 21 or more
244LLBTG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#7DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1T2BS1MTier 2
Before Step Therapy1 or more
244LLBTG1T2AS1MTier 2
After Step Therapy1 or more
244LLBTG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1T21MTier 21 or more
244LLBTG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#8DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1T2BS1MTier 2
Before Step Therapy1 or more
244LLBTG1T2AS1MTier 2
After Step Therapy1 or more
244LLBTG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1T21MTier 21 or more
244LLBTG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#9DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1T2BS1MTier 2
Before Step Therapy1 or more
244LLBTG1T2AS1MTier 2
After Step Therapy1 or more
244LLBTG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1T21MTier 21 or more
244LLBTG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#10DOD Uniform Formulary Class:LEUKEMIA AND LYMPHOMA AGENTSP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:BRUTON TYROSINE KINASE INHIBITORSQuotes due:June 13, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Branded AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 1244LLBTG1T2BS1MTier 2
Before Step Therapy1 or more
244LLBTG1T2AS1MTier 2
After Step Therapy1 or more
244LLBTG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: No step therapy. One or more.
Scenario 2244LLBTG1T21MTier 21 or more
244LLBTG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

File details come from the government source that posted it. Updated .